Date:7/29/2009

data) June 30, June 30, -------- -------- 2009 2008* 2009 2008* ---- ---- ---- ---- (unaudited) (unaudited) Revenues: Net product sales $81,873 $65,437 $142,063 $116,374 Costs and Expenses: Cost of sales (excluding amortization of product rights) 14,121 2,386 18,049 4,304 Research and development 12,467 14,584 32,151 28,999 Selling, general and administrative 23,612 16,605 47,990 30,004 Intangible amortization 7,424 2,145 14,681 3,833 Goodwill impairment - - 65,099 - --- --- ------ --- Total costs and expenses 57,624 35,720 177,970 67,140 ------ ------ ------- ------ Operating income (loss) 24,249 29,717 (35,907) 49,234 Interest income 105 4,067 250 10,378 Interest expense (2,677) (3,218) (5,986) (6,346) Gain on senior convertible note repurchase - - 9,079 - --- --- ----- --- Income (loss) before income tax expense 21,677 30,566 (32,564) 53,266 Income tax expense 5,625 7,783 10,599 14,098 ----- ----- ------ ------ Net income (loss) $16,052 $22,783 $(43,163) $39,168 ======= =======
'/>"/>

SOURCE ViroPharma Incorporated Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema